AbbVie a global biopharmaceutical company announced that data on HUMIRA® (adalimumab), investigational medicines and research, including real-world evidence, aiming to improve clinical outcomes for patients with rheumatologic diseases, will be presented at the Annual European Congress of Rheumatology (EULAR 2016), June 8 – 11, in London. These data add to the body of evidence supporting the safety and efficacy of adalimumab, an anti-TNF therapy, and AbbVie's continued commitment to innovation across immunology.
"At EULAR 2016, AbbVie is presenting scientific research on adalimumab across autoimmune diseases, including new areas like non-infectious uveitis, where there is an unmet need for patients," said Dominik Hochli, vice president, global medical affairs, AbbVie. "Building on more than a decade of experience in rheumatology, we are focused on expanding treatment options with new therapies to further improve patient care within the rheumatology community across the globe."
Data from the VISUAL Phase 3 pivotal studies evaluating the efficacy and safety of adalimumab in patients with non-infectious intermediate, posterior and panuveitis will be presented. Non-infectious uveitis is a group of diseases characterized by inflammation of the uvea, the middle layer of the eye, which can lead to reduced vision or vision loss.1 Adalimumab is not currently approved to treat any form of uveitis.
AbbVie will also present research on investigational medicines looking at multiple scientific approaches and novel solutions to help improve patient care for a variety of autoimmune diseases. New Phase 2 data on ABT-494, an investigational, once-daily, oral selective JAK1 inhibitor for the treatment of rheumatoid arthritis, will be presented. The Phase 3 clinical program is currently underway.
Since first gaining approval 13 years ago, HUMIRA has been approved in more than 90 countries, and is currently being used to treat more than 989,000 patients worldwide2 across 13 globally approved indications.3,4
About HUMIRA in the European Union3
HUMIRA is currently indicated for the treatment of adults with moderate to severe rheumatoid arthritis, severe active progressive rheumatoid arthritis not previously treated with methotrexate, active polyarticular juvenile idiopathic arthritis in patients from the age 2 years, active enthesitis-related arthritis in patients from 6 years of age and older, severe active ankylosing spondylitis (AS), severe axial spondyloarthritis without radiographic evidence of AS but with objective signs of inflammation by elevated CRP and / or MRI, active and progressive psoriatic arthritis, moderate to severe chronic plaque psoriasis in adults and severe chronic plaque psoriasis in children and adolescents from 4 years of age, active moderate to severe hidradenitis suppurativa (HS) (acne inversa) in adults with an inadequate response to conventional systemic HS therapy, moderately to severely active Crohn's disease in adults and paediatric patients (from 6 years of age) and moderately to severely active ulcerative colitis in adults.
For more information, read the Humira SmPC: https://www.medicines.org.uk/emc/search/?q=humira
AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. Together with its wholly-owned subsidiary, Pharmacyclics, AbbVie employs more than 28,000 people worldwide and markets medicines in more than 170 countries. For further information on the company and its people, portfolio and commitments, please visit www.abbvie.com.
- Durrani OM, Tehrani NN, Marr JE, Moradi P, Stavrou P, Murray PI. Degree, duration, and causes of visual loss in uveitis. Br J of Ophthalmol. 2004;88(9):1159-1162.
- AbbVie Data on File.
- Humira [summary of product characteristics]. AbbVie Inc.; May 2016. https://www.medicines.org.uk/emc/search/?q=humira. Updated May 11, 2016. Accessed May 26, 2016
- Pharmaceutical and Medical Devices Agency (PMDA) website. New Drugs Approved in FY 2013. Available at:http://www.pmda.go.jp/files/000153463.pdf#page=1. Accessed May 26, 2016.
+1 (847) 935-0580
+1 (847) 935-2211
+1 (847) 937-2644